TY - JOUR
T1 - Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults
AU - Cherry, James D.
AU - Chang, Swei Ju
AU - Klein, David
AU - Lee, Martin
AU - Barenkamp, Steve
AU - Bernstein, David
AU - Edelman, Robert
AU - Decker, Michael D.
AU - Greenberg, David P.
AU - Keitel, Wendy
AU - Treanor, John
AU - Ward, Joel I.
N1 - Funding Information:
Potential conflicts of interest. J.D.C.: Speaker’s bureau for Glaxo-SmithKline and Aventis. R.E.: Research funding from Aventis Pasteur Connaught. M.D.: Employed by Aventis Pasteur; member of speaker’s bureaus for Aventis Pasteur, Chiron, GlaxoSmithKline, Pasteur Merieux, Connaught, Merck, and Wyeth; consultant for GlaxoSmithKline, Meade Johnson, Medicalliance, Pasteur Merieux, Connaught, Merck, and PRO/COM International; and research funding from Chiron, GlaxoSmithKline, Merck, and Wyeth. All other authors: no conflicts.
PY - 2004/12/1
Y1 - 2004/12/1
N2 - Serum specimens were obtained from all subjects in the adolescent and adult acellular pertussis (aP) vaccine efficacy trial before and after immunization to study the prevalence of IgG and IgA antibody and geometric mean titers to 4 Bordetella pertussis antigens. Of 1793 adolescents and adult subjects who received aP vaccine, only 20%, 68%, 59%, and 39% had concentrations of IgG antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3, respectively, that were greater than or equal to the limit of quantitation of the enzyme-linked immunosorbent assay used in the analysis. There was minimal variation in antibody prevalence with respect to geographic area, age, sex, or race.
AB - Serum specimens were obtained from all subjects in the adolescent and adult acellular pertussis (aP) vaccine efficacy trial before and after immunization to study the prevalence of IgG and IgA antibody and geometric mean titers to 4 Bordetella pertussis antigens. Of 1793 adolescents and adult subjects who received aP vaccine, only 20%, 68%, 59%, and 39% had concentrations of IgG antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3, respectively, that were greater than or equal to the limit of quantitation of the enzyme-linked immunosorbent assay used in the analysis. There was minimal variation in antibody prevalence with respect to geographic area, age, sex, or race.
UR - http://www.scopus.com/inward/record.url?scp=9644270482&partnerID=8YFLogxK
U2 - 10.1086/425003
DO - 10.1086/425003
M3 - Article
AN - SCOPUS:9644270482
SN - 1058-4838
VL - 39
SP - 1715
EP - 1718
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -
